Zacks Small Cap Forecasts Reduced Earnings for Soligenix

Soligenix, Inc. (NASDAQ:SNGX) – Stock analysts at Zacks Small Cap dropped their FY2025 earnings per share estimates for Soligenix in a research report issued to clients and investors on Wednesday, March 26th. Zacks Small Cap analyst D. Bautz now expects that the biopharmaceutical company will post earnings per share of ($3.09) for the year, down from their prior forecast of ($2.93). The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s FY2026 earnings at ($2.02) EPS.

Soligenix (NASDAQ:SNGX) last posted its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). Soligenix had a negative return on equity of 223.29% and a negative net margin of 1,473.38%. The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. During the same period last year, the firm earned ($12.66) earnings per share.

Soligenix Stock Performance

Shares of Soligenix stock opened at $2.27 on Friday. Soligenix has a 52 week low of $1.83 and a 52 week high of $14.92. The stock has a market capitalization of $5.70 million, a price-to-earnings ratio of -0.30 and a beta of 2.03. The firm has a fifty day moving average of $2.35 and a two-hundred day moving average of $3.08.

Hedge Funds Weigh In On Soligenix

An institutional investor recently raised its position in Soligenix stock. Geode Capital Management LLC grew its stake in Soligenix, Inc. (NASDAQ:SNGX) by 42.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,094 shares of the biopharmaceutical company’s stock after acquiring an additional 7,729 shares during the quarter. Geode Capital Management LLC owned 1.04% of Soligenix worth $71,000 at the end of the most recent quarter. Institutional investors own 3.60% of the company’s stock.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.